FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1539037801> ?p ?o ?g. }

• W1539037801 abstract "One hundred and seventeen patients with severe aplastic anemia (SAA) were treated at our institution between 1976 and 1990 with antilymphocyte globulin (ALG) therapy. Seventy-nine (68%) are alive and probability of survival at 14 years, according to Kaplan and Meier, is 62% +/- 12%. Twenty-six patients developed a late clonal complication: 11 had a myelodysplastic syndrome (MDS) and 17 had paroxysmal nocturnal hemoglobinuria (PNH); two patients had both. The cumulative risk at 10 years is 42%. The development of MDS/PNH after SAA directly affects survival. The probability of being alive at 14 years is 81% +/- 10% for patients with stable disease and 36% +/- 13% for those with clonal evolution (P = .001). To look for predictive signs, we reevaluated peripheral blood and bone marrow cytomorphology at presentation, during regeneration, and in remission. We examined the peripheral blood values for hemoglobin, reticulocytes, granulocytes, thrombocytes, mean corpuscular volume (MCV), and fetal hemoglobin, as well as bone marrow for cellularity, erythropoiesis, myelopoiesis, and megakaryopoiesis. ALG therapy induces slow and incomplete recovery. Although in “remission,” ALG patients have lower hemoglobin values, higher reticulocyte counts, lower granulocyte and platelet values, and a higher MCV and fetal hemoglobin than normal controls. They retain a reduced number of megakaryocytes and a persistence of atypical monocytes in bone marrow morphology as stigmata of their disease. Patients with late clonal complications show distinct morphologic abnormalities: patients with PNH have higher MCVs, higher granulocyte and reticulocyte counts, and more dyserythropoiesis at diagnosis and a lower hemoglobin with an increased proportion of erythroblasts in the bone marrow in “remission.” Patients who later developed MDS are not different from the total patient population at diagnosis. After therapy, these patients are characterized by the presence of ring sideroblasts and atypical monocytes during regeneration and by a persistent increase in MCV, a higher fetal hemoglobin, lower granulocyte values, and megakaryocytic dysplasia during “remission.” Thus, routine morphologic follow-up examination of blood and bone marrow can discover patients at risk for late hematologic complications after ALG therapy." @default.
• W1539037801 created "2016-06-24" @default.
• W1539037801 creator A5010990894 @default.
• W1539037801 creator A5042539675 @default.
• W1539037801 creator A5072582820 @default.
• W1539037801 creator A5079480540 @default.
• W1539037801 creator A5084352990 @default.
• W1539037801 creator A5090405271 @default.
• W1539037801 date "1992-07-15" @default.
• W1539037801 modified "2023-10-03" @default.
• W1539037801 title "Morphology in patients with severe aplastic anemia treated with antilymphocyte globulin" @default.
• W1539037801 cites W17773599 @default.
• W1539037801 cites W1851142847 @default.
• W1539037801 cites W1979300931 @default.
• W1539037801 cites W1988158114 @default.
• W1539037801 cites W1993411007 @default.
• W1539037801 cites W2011989789 @default.
• W1539037801 cites W2016125215 @default.
• W1539037801 cites W2032388436 @default.
• W1539037801 cites W2033610749 @default.
• W1539037801 cites W2038252730 @default.
• W1539037801 cites W2053648654 @default.
• W1539037801 cites W2054370945 @default.
• W1539037801 cites W2055023639 @default.
• W1539037801 cites W2055079427 @default.
• W1539037801 cites W2055482423 @default.
• W1539037801 cites W2083048416 @default.
• W1539037801 cites W2168725807 @default.
• W1539037801 cites W2168807786 @default.
• W1539037801 cites W2268156776 @default.
• W1539037801 cites W2403659742 @default.
• W1539037801 cites W2415085755 @default.
• W1539037801 cites W2416422794 @default.
• W1539037801 cites W2432405017 @default.
• W1539037801 cites W2435718656 @default.
• W1539037801 doi "https://doi.org/10.1182/blood.v80.2.337.bloodjournal802337" @default.
• W1539037801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1627795" @default.
• W1539037801 hasPublicationYear "1992" @default.
• W1539037801 type Work @default.
• W1539037801 sameAs 1539037801 @default.
• W1539037801 citedByCount "21" @default.
• W1539037801 countsByYear W15390378012017 @default.
• W1539037801 countsByYear W15390378012019 @default.
• W1539037801 crossrefType "journal-article" @default.
• W1539037801 hasAuthorship W1539037801A5010990894 @default.
• W1539037801 hasAuthorship W1539037801A5042539675 @default.
• W1539037801 hasAuthorship W1539037801A5072582820 @default.
• W1539037801 hasAuthorship W1539037801A5079480540 @default.
• W1539037801 hasAuthorship W1539037801A5084352990 @default.
• W1539037801 hasAuthorship W1539037801A5090405271 @default.
• W1539037801 hasBestOaLocation W15390378011 @default.
• W1539037801 hasConcept C104317684 @default.
• W1539037801 hasConcept C105580179 @default.
• W1539037801 hasConcept C126322002 @default.
• W1539037801 hasConcept C142724271 @default.
• W1539037801 hasConcept C172680121 @default.
• W1539037801 hasConcept C203014093 @default.
• W1539037801 hasConcept C2776317666 @default.
• W1539037801 hasConcept C2777346216 @default.
• W1539037801 hasConcept C2778248108 @default.
• W1539037801 hasConcept C2778403015 @default.
• W1539037801 hasConcept C2779234561 @default.
• W1539037801 hasConcept C2779703530 @default.
• W1539037801 hasConcept C2780007613 @default.
• W1539037801 hasConcept C2781440808 @default.
• W1539037801 hasConcept C54355233 @default.
• W1539037801 hasConcept C55493867 @default.
• W1539037801 hasConcept C71924100 @default.
• W1539037801 hasConcept C86803240 @default.
• W1539037801 hasConcept C90924648 @default.
• W1539037801 hasConceptScore W1539037801C104317684 @default.
• W1539037801 hasConceptScore W1539037801C105580179 @default.
• W1539037801 hasConceptScore W1539037801C126322002 @default.
• W1539037801 hasConceptScore W1539037801C142724271 @default.
• W1539037801 hasConceptScore W1539037801C172680121 @default.
• W1539037801 hasConceptScore W1539037801C203014093 @default.
• W1539037801 hasConceptScore W1539037801C2776317666 @default.
• W1539037801 hasConceptScore W1539037801C2777346216 @default.
• W1539037801 hasConceptScore W1539037801C2778248108 @default.
• W1539037801 hasConceptScore W1539037801C2778403015 @default.
• W1539037801 hasConceptScore W1539037801C2779234561 @default.
• W1539037801 hasConceptScore W1539037801C2779703530 @default.
• W1539037801 hasConceptScore W1539037801C2780007613 @default.
• W1539037801 hasConceptScore W1539037801C2781440808 @default.
• W1539037801 hasConceptScore W1539037801C54355233 @default.
• W1539037801 hasConceptScore W1539037801C55493867 @default.
• W1539037801 hasConceptScore W1539037801C71924100 @default.
• W1539037801 hasConceptScore W1539037801C86803240 @default.
• W1539037801 hasConceptScore W1539037801C90924648 @default.
• W1539037801 hasLocation W15390378011 @default.
• W1539037801 hasOpenAccess W1539037801 @default.
• W1539037801 hasPrimaryLocation W15390378011 @default.
• W1539037801 hasRelatedWork W105676805 @default.
• W1539037801 hasRelatedWork W15191073 @default.
• W1539037801 hasRelatedWork W1663740507 @default.
• W1539037801 hasRelatedWork W1836055088 @default.
• W1539037801 hasRelatedWork W1851142847 @default.
• W1539037801 hasRelatedWork W1870843212 @default.
• W1539037801 hasRelatedWork W196567407 @default.
• W1539037801 hasRelatedWork W1987922702 @default.

• next